Fair Value Distribution — percentile bands
26.9% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
5.4%/yr
±4.9% · revenue growth to justify current price
FCF-Based Reverse DCF
8.0%/yr
±3.1% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
Upgrade to premium for full distribution data, sensitivity analysis, and segment breakdowns.
Sign in to unlockMedtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally.
No Eagle analysis yet. Request a full review including conviction score, bull/bear cases, and thesis.
No analysis yet
No analysis yet
Q3 beat on revenue (+9% YoY to .0B) driven by Cardiovascular (+14%) and Diabetes (+15%), but GAAP EPS declined to /bin/zsh.89 vs .01 as restructuring ballooned (M) and litigation charges hit (M). Non-...